应用AHA PREVENT心血管风险方程后他汀与降压治疗资格的预测变化
该研究基于2011年至2020年3月美国国家健康与营养调查的7765名30至79岁成人的全国代表性横断面样本,估算将AHA PREVENT方程替代 pooled cohort equations(PCEs)并沿用现有ACC/AHA指南阈值时,风险分类、治疗资格和临床结局的变化。结果显示,约53.0%的成人被重新分类至更低风险类别,仅0.41%升至更高类别;他汀治疗资格减少1430万(95% CI 1260万-1590万),降压治疗资格减少262万(95% CI 202万-321万)。作者估计10年内这些治疗资格减少可能导致新增10.7万例心肌梗死或卒中,且资格变化对男性的影响约为女性的两倍,黑人成人受影响比例高于白人成人。
要点
- 应用PREVENT方程后,53.0%(95% CI 51.2%-54.8%)的美国成人被重新分类至更低ACC/AHA风险类别,仅0.41%(95% CI 0.25%-0.62%)升至更高类别。
- 他汀治疗资格预计减少1430万(95% CI 1260万-1590万),降压治疗资格减少262万(95% CI 202万-321万)。
- 作者估计10年内治疗资格减少可能导致新增10.7万例心肌梗死或卒中。
- 资格变化对男性的影响约为女性的两倍,黑人成人受影响比例高于白人成人。
适用人群与场景
- 美国30至79岁成人,来自2011年至2020年3月国家健康与营养调查的全国代表性横断面样本(n=7765;中位年龄53岁;51.3%为女性)。
研究设计与关键结果
- 研究类型:全国代表性横断面样本分析;样本量7765名美国30至79岁成人;数据来源为2011年至2020年3月国家健康与营养调查(应答率47%至70%)。
- 主要结果:应用PREVENT方程后,53.0%(95% CI 51.2%-54.8%)的成人被重新分类至更低ACC/AHA风险类别,0.41%(95% CI 0.25%-0.62%)被重新分类至更高风险类别。
- 治疗资格变化:他汀治疗资格减少1430万(95% CI 1260万-1590万),降压治疗资格减少262万(95% CI 202万-321万)。
- 临床结局:估计10年内治疗资格减少可能导致新增10.7万例心肌梗死或卒中。
- 亚组影响:资格变化对男性的影响约为女性的两倍,黑人成人受影响比例高于白人成人。
证据类型、等级与局限
- 证据类型:基于全国代表性横断面样本的预测分析;局限:原文未报告局限性。
对床旁实践的改变
- 作者指出,PREVENT方程产生的ASCVD风险预测低于PCEs,将其应用于现有治疗阈值会降低他汀和降压治疗资格,可能影响预防治疗的启动决策。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Since 2013, the American College of Cardiology (ACC) and American Heart Association (AHA) have recommended the pooled cohort equations (PCEs) for estimating the 10-year risk of atherosclerotic cardiovascular disease (ASCVD). An AHA scientific advisory group recently developed the Predicting Risk of cardiovascular disease EVENTs (PREVENT) equations, which incorporated kidney measures, removed race as an input, and improved calibration in contemporary populations. PREVENT is known to produce ASCVD risk predictions that are lower than those produced by the PCEs, but the potential clinical implications have not been quantified.
OBJECTIVE: To estimate the number of US adults who would experience changes in risk categorization, treatment eligibility, or clinical outcomes when applying PREVENT equations to existing ACC and AHA guidelines.
DESIGN, SETTING, AND PARTICIPANTS: Nationally representative cross-sectional sample of 7765 US adults aged 30 to 79 years who participated in the National Health and Nutrition Examination Surveys of 2011 to March 2020, which had response rates ranging from 47% to 70%.
MAIN OUTCOMES AND MEASURES: Differences in predicted 10-year ASCVD risk, ACC and AHA risk categorization, eligibility for statin or antihypertensive therapy, and projected occurrences of myocardial infarction or stroke.
RESULTS: In a nationally representative sample of 7765 US adults aged 30 to 79 years (median age, 53 years; 51.3% women), it was estimated that using PREVENT equations would reclassify approximately half of US adults to lower ACC and AHA risk categories (53.0% [95% CI, 51.2%-54.8%]) and very few US adults to higher risk categories (0.41% [95% CI, 0.25%-0.62%]). The number of US adults receiving or recommended for preventive treatment would decrease by an estimated 14.3 million (95% CI, 12.6 million-15.9 million) for statin therapy and 2.62 million (95% CI, 2.02 million-3.21 million) for antihypertensive therapy. The study estimated that, over 10 years, these decreases in treatment eligibility could result in 107 000 additional occurrences of myocardial infarction or stroke. Eligibility changes would affect twice as many men as women and a greater proportion of Black adults than White adults.
CONCLUSION AND RELEVANCE: By assigning lower ASCVD risk predictions, application of the PREVENT equations to existing treatment thresholds could reduce eligibility for statin and antihypertensive therapy among 15.8 million US adults.
参考来源
- Diao JA, Shi I, Murthy VL, et al. Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations. JAMA. 2024. PMID: 39073797. doi:10.1001/jama.2024.12537
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。